Last updated June 3, 2026 Editorial policy A Weight-Loss Drug With an Unexpected Benefit If youve been anywhere near the news in the past two years, youve heard of GLP-1 receptor agonists drugs like Ozempic, Wegovy, and Mounjaro that have transformed weight loss and diabetes management
Generic versions typically launch 6-12 months after patent expiration, but that timeline assumes no patent disputes or regulatory delays
Not necessarily, but they should be monitored closely by their healthcare provider
ABSTRACT: Glucagon-like peptide-1 (GLP-1) receptor agonists are an increasingly popular class of glucose-lowering agents for the treatment of type 2 diabetes (T2DM), owing to their robust glucose-lowering effects, low risk of hypoglycemia, and potential to induce weight loss
Value: When checking prices, compare the dose per capsule and the number of servings per container to ensure the best value